Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12624639 | 0.92 | MAPT (0.40) | MAPTKDM4ETSHRALDH1A1L3MBTL1 | |
| SCHEMBL12622983 | 0.90 | ALDH1A1 (0.45) | MAPTKDM4ETSHRALDH1A1L3MBTL1 | |
| SCHEMBL12622989 | 0.88 | MAPT (0.41) | MAPTKDM4ETSHRALDH1A1L3MBTL1 | |
| SCHEMBL12623197 | 0.88 | KDM4E (0.42) | MAPTKDM4ETSHRALDH1A1L3MBTL1 | |
| SCHEMBL832275 | 0.88 | KDM4E (0.42) | MAPTKDM4ETSHRALDH1A1L3MBTL1 | |
| SCHEMBL12623056 | 0.86 | MAPK1 (0.41) | MAPTKDM4ETSHRALDH1A1L3MBTL1 | |
| SCHEMBL12623091 | 0.84 | MAPT (0.39) | MAPTKDM4ETSHRALDH1A1L3MBTL1 | |
| SCHEMBL10257060 | 0.82 | PPARG (0.35) | MAPTKDM4ETSHRPKMTP53 | |
| SCHEMBL12623004 | 0.82 | ALDH1A1 (0.37) | MAPTKDM4ETSHRALDH1A1TNIK | |
| SCHEMBL12623594 | 0.81 | GRIN1 (0.36) | KDM4EALDH1A1PKMTNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-05-05 | — | — | US | disclosed |
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | IDO1, IDO2, ZC3HAV1 | MAPT 424/4885KDM4E 2071/4885TSHR 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.